StockNews.AI
BIOA
StockNews.AI
215 days

BioAge Labs, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA

1. BioAge Labs faces a class action lawsuit from affected investors. 2. Lawsuit stems from safety concerns over lead product candidate azelaprag. 3. Stock price plummeted from $20.09 to $4.65 after the announcement. 4. Investors are encouraged to register for potential recovery. 5. The deadline for lead plaintiff appointment is March 10, 2025.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The rapid decline in stock price following adverse safety news is significant. Similar cases often pressure stock prices long-term.

How important is it?

The lawsuit directly relates to BioAge's recent product developments affecting investor perception heavily.

Why Long Term?

Ongoing legal issues can hinder investor confidence and recovery prospects. Historical cases show extended impacts from class actions.

Related Companies

BIOA
, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA). Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=123060&from=4 CLASS PERIOD: This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September 26, 2024. ALLEGATIONS: According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs.  Following this news, BioAge's stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024. DEADLINE: March 10, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=123060&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of BIOA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is March 10, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected]Phone: (646) 453-8903 SOURCE The Gross Law Firm WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News